Curient presented its dual payload ADC candidate 'QP101' and its strategy for developing a new proteasome inhibitor (PI) ...
On June 10, Alteogen, a bio-platform company, announced that it had released preclinical experimental results on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results